A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novelwise Pharmaceutical Corporation
Tango Therapeutics, Inc.
NaviFUS Corporation
Hoosier Cancer Research Network
Stemline Therapeutics, Inc.
Weill Medical College of Cornell University
Stanford University
National Institutes of Health Clinical Center (CC)
Baptist Health South Florida
Neonc Technologies, Inc.
Stanford University
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
Hoosier Cancer Research Network
University of Utah
Wayshine Biopharm, Inc.
Servier
InSightec
Cedars-Sinai Medical Center
Eikon Therapeutics
Case Comprehensive Cancer Center
InSightec
Hunan Cancer Hospital
Northwell Health
Northwell Health
Plus Therapeutics
Essen Biotech
Fudan University